Ocular Therapeut Cmn (OCUL) 7.14 $OCUL Research Reports

New Post Public Reply Private Reply Replies (0) Message Board

Sep 21, 2016 at 11:07 PM

Ocular Therapeut Cmn (OCUL) 7.14 $OCUL

Research Reports Initiation on Biotech Stocks -- Ocular Therapeutix, Infinity Pharma, Lpath, and Idera Pharma
PR Newswire - Mon Sep 19, 7:59AM CDT
The NASDAQ Composite ended the trading session at 5,244.57, down 0.10 on Friday, September 16, 2016. Today, Stock-Callers.com looks at the performance of the following biotech companies for the recent few weeks: Ocular Therapeutix Inc. (NASDAQ: OCUL), Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Lpath Inc. (NASDAQ: LPTN), and Idera Pharmaceuticals Inc. (NASDAQ: IDRA). You can access of our complimentary research reports on these stocks now at:
IDRA: 2.70 (-0.14), INFI: 1.47 (-0.07), LPTN: 3.52 (+0.18), OCUL: 7.14 (+0.03)

Lifshitz & Miller Law Firm Announces Investigation of AECOM, American Farmland Company, Centene Corp., Cepheid, Cray Inc., Echo Global Logistics, Inc., Ocular Therapeutix, Inc., and Pure Storage, Inc.
PR Newswire - Tue Sep 13, 2:18PM CDT
AECOM (ACM)
CNC: 68.28 (+1.39), ECHO: 23.25 (+0.25), AFCO: 7.56 (-0.02), PSTG: 13.66 (+0.40), CPHD: 52.53 (+0.04), ACM: 28.17 (+0.57), CRAY: 23.79 (+0.41), OCUL: 7.14 (+0.03)

Ocular Therapeutix(TM) to Participate in the Morgan Stanley Global Healthcare Conference
BusinessWire - Wed Aug 31, 3:05PM CDT
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Monday, September 12, 2016 at 4:15 p.m. ET. The conference will be held at the Grand Hyatt Hotel in New York, NY.
OCUL: 7.14 (+0.03), MS: 31.92 (+0.22)

Biotech Companies With Huge Potential
ACCESSWIRE - Wed Aug 31, 8:24AM CDT
LAS VEGAS, NV / ACCESSWIRE / August 31, 2016 / Outside of the energy sector, the past year, there has not been any sector under more pressure than biotechnology. As an example of the bearish bias, the ProShares Ultra NASDAQ Biotechnology ETF (NASDAQ: BIB) has slumped from a record high last July at $106.10 to a low of $33.97 late in June, representing a top-to-bottom decline of 68%. For the most part, biotechs of all sizes have felt the pain. Markets are always cyclical and I believe the biotech beat down is reaching its bottom and will soon begin to reverse the trend. From a technical perspective, I think that BIB breaking over $50 again will be a sign of the reversal (it's currently around $43).
BIB: 51.33 (+0.65), GSK: 43.21 (+0.15), OCUL: 7.14 (+0.03)

Ocular Therapeutix(TM) Reports Second Quarter 2016 Financial Results and Provides Corporate Update
BusinessWire - Tue Aug 09, 6:30AM CDT
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the second quarter ended June 30, 2016.
OCUL: 7.14 (+0.03)

Ocular Therapeutix(TM) Announces Presentation at the Ophthalmology Innovation Summit (OIS) at the American Society of Retina Specialists (ASRS)
BusinessWire - Fri Aug 05, 7:00AM CDT
Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Jonathan Talamo, M.D., Chief Medical Officer, will present at the Ophthalmology Innovation Summit (OIS) at the American Society of Retina Specialists (ASRS) on Monday, August 8, 2016, in San Francisco, CA.
OCUL: 7.14 (+0.03)

Why is Ocular Therapeutics (OCUL) Surging 36% Today?
Afrasiab Mian - Zacks Investment Research - Thu Aug 04, 2:49PM CDT
Ocular Therapeutics (OCUL) is up 35.7% in afternoon trading after announcing that the FDA's concerns regarding the company's New Drug Application (NDA) appear to have been addressed.
OCUL: 7.14 (+0.03)

Ocular Therapeutix(TM) Provides Update on NDA for DEXTENZA(TM) for the Treatment of Post-Surgical Ocular Pain
BusinessWire - Wed Aug 03, 3:16PM CDT
Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today provided an update on the status of its New Drug Application (NDA) for DEXTENZA(TM) (dexamethasone insert) 0.4 mg, for intracanalicular use in the treatment of ocular pain occurring after ophthalmic surgery.
OCUL: 7.14 (+0.03)

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
BusinessWire - Wed Aug 03, 5:35AM CDT
Khang & Khang LLP (the "Firm"

announces that it is investigating claims against Ocular Therapeutix, Inc. ("Ocular" or the "Company"

(Nasdaq: OCUL) concerning possible violations of federal securities laws.
OCUL: 7.14 (+0.03)

Ocular Therapeutix(TM) to Report Second Quarter 2016 Financial Results
BusinessWire - Tue Aug 02, 3:05PM CDT
Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report second quarter 2016 financial results on Tuesday, August 9, 2016. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 8:30 a.m. Eastern Time to review the Company's financial results and provide a business update.
OCUL: 7.14 (+0.03)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ocular Therapeutix, Inc. - OCUL
ACCESSWIRE - Tue Aug 02, 1:17PM CDT
NEW YORK, NY / ACCESSWIRE / August 2, 2016 / Pomerantz LLP is investigating claims on behalf of investors of Ocular Therapeutix, Inc. ("Ocular" or the "Company"

(NASDAQ: OCUL). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
OCUL: 7.14 (+0.03)

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Ocular Therapeutix, Inc. and Advises Investors with Losses to Contact the Firm
BusinessWire - Mon Aug 01, 9:43AM CDT
Lundin Law PC (http://lundinlawpc.com/) announces it is investigating claims against Ocular Therapeutix ("Ocular" or the "Company"

(Nasdaq: OCUL) concerning possible violations of federal securities laws.
OCUL: 7.14 (+0.03)

Glancy Prongay & Murray Commences Investigation on Behalf of Ocular Therapeutix, Inc. Investors
BusinessWire - Fri Jul 29, 2:31PM CDT
Glancy Prongay & Murray LLP ("GPM"

announces an investigation on behalf of investors of Ocular Therapeutix, Inc. ("Ocular" or the "Company"

(NASDAQ: OCUL) concerning the Company and its officers' possible violations of federal securities laws. GPM is preparing a lawsuit on behalf of injured investors.
OCUL: 7.14 (+0.03)

IMPORTANT SHAREHOLDER NOTICE: Goldberg Law PC Announces An Investigation of Claims Against Ocular Therapeutix, Inc. And Advises Investors With Losses To Contact The Firm
BusinessWire - Wed Jul 27, 5:14PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Ocular Therapeutix, Inc. ("Ocular" or the "Company"

(Nasdaq: OCUL). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
OCUL: 7.14 (+0.03)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding Possible Violations of Federal Securities Laws by Certain Officers and Directors of Ocular Therapeutix Inc.
BusinessWire - Wed Jul 27, 3:02PM CDT
Levi & Korsinsky announces it has commenced an investigation of Ocular Therapeutix Inc. (NASDAQ:OCUL) ("Ocular Therapeutix"

concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
OCUL: 7.14 (+0.03)

INVESTOR ALERT: Investigation of Ocular Therapeutix, Inc. Announced by Law Offices of Howard G. Smith
BusinessWire - Wed Jul 27, 1:45PM CDT
Law Offices of Howard G. Smith announces an investigation on behalf of investors of Ocular Therapeutix, Inc. ("Ocular" or the "Company"

(NASDAQ: OCUL) concerning the Company and its officers' possible violations of federal securities laws.
OCUL: 7.14 (+0.03)

Chesapeake Energy, Devon and Ciber climb, AbbVie slips
AP - Mon Jun 06, 3:29PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Monday:
HERO: 1.22 (+0.01), DVN: 42.17 (+1.51), CHK: 6.74 (+0.18), C: 46.90 (+0.36), MAN: 69.21 (+1.58), CBR: 1.25 (-0.08), TSN: 75.69 (+1.13), OCUL: 7.14 (+0.03)

Ocular Therapeutix(TM) Announces Topline Results of Second Phase 3 Clinical Trial of DEXTENZA(TM) for the Treatment of Allergic Conjunctivitis
BusinessWire - Mon Jun 06, 6:00AM CDT
--Conference call today at 8:30 am Eastern Time
OCUL: 7.14 (+0.03)

Ocular Therapeutix(TM) to Present at Two Upcoming Investor Conferences
BusinessWire - Thu Jun 02, 3:05PM CDT
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:
OCUL: 7.14 (+0.03)

Ocular Therapeutix(TM) Reports First Quarter 2016 Financial Results and Provides Corporate Update
BusinessWire - Tue May 10, 6:00AM CDT
--Second Phase 3 clinical trial for DEXTENZA for the treatment of allergic conjunctivitis fully enrolled; topline results expected June 2016
OCUL: 7.14 (+0.03)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Honoring Boston's Architects Changing the Game

Celebrating Architecture's Influencers in Boston Every now and then, a profession needs a wake-up call. Stirring the pot, shaking the roots, call it what you will, but when folks rally together with a shared vision, change doesn't just seem possible — it's inevitable. On November 12, the Boston Society of Architects (BSA) and Architecture in Common (AiC) did just that...

SOCSA: The Future of Safety in Confined Spaces?

Autonomous Tech Meets Safety Regulations Some days innovation hits like a ton of bricks, and here we go again—this time with a gizmo aiming to shake up the safety game in confined spaces. Enter the SOCSA, the Self Operating Confined Space Attendant, designed by a seasoned agriculture worker who's had a ringside seat to enough OSHA rule breaches to fill a book. But ain't...

Retirement Dreams Dashed: 61% Withdraw Early

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

NVIDIA Faces Legal Turbulence: CEO's Exit Sparks Chaos

Jensen Huang's Sudden Exit: A Barrage of Headlines In what feels like a blow delivered by a sledgehammer, NVIDIA is rocked by the abrupt resignation of its iconic co-founder and CEO, Jensen Huang. This isn't some quiet departure into the night. Nope, it's more like a cannonball being fired into the investor lounge, leaving a wreckage for all to navigate through. Huang's...

Perpetua Reports Q3 2026 Results, Progress on Project

A Steady Climb for Perpetua Resources It's like watching a boxer steadily climb the ranks, waiting for the big title fight. That's the scene with Perpetua Resources (NASDAQ:PPTA) as their Q3 2026 financial results hit the wires. No confetti cannons this time, just solid, gritty steps towards a promising future. Q3 Financial Results: A Prudent Path The financials for...

Sino Bio Speeds AI Drug Discovery with 4RISE Launch

AI Meets Real-World Validation In the world of cutting-edge biotech, Sino Biological is turning heads with its latest move. If you're in the game of AI-driven drug discovery, their new 4RISE™ high-throughput wet-lab validation services could be the breakthrough you've been waiting for. Why? Well, the promise of AI is dazzling, but it all boils down to how fast you can...

Windward Bio Surges 68% in Nasdaq Debut

By Ryan Hughes Updated Nov 13, 2026 Category News Views 134

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Fluence Energy Faces Class Action: Investor Insights

Investor Blues: Fluence Under the Weather If you've been keeping an eye on Fluence Energy (NASDAQ:FLNC), you're probably clutching your metaphorical pearls right now. Here's the scoop: on November 2, 2026, the stock took another nosedive—dropping nearly 9%—as the company announced that both CEO Julian Nebreda and CFO Ahmad Pasha had packed their bags. A leadership...

Missoula Inventor Offers Handy Phone Solution on the Move

Adjustable Convenience for the Modern Commuter When you're commuting or just lounging around, less hand strain and more comfort sounds like a no-brainer, right? Well, an inventive soul from Missoula, Montana, just might have cracked this little nut with a gizmo they're calling the COMMUTER PHONE. Imagine never having to juggle your phone during those bumpy moments on the...

PangeAI and Sky Blue Transform Data Center Decisions

Just when you thought the incessant trials of picking a prime data center site couldn’t get any more grueling or expensive, enter PangeAI and its brand-new ally, Sky Blue Impact. These tech firms have partnered up to speed up what has traditionally been a sluggish, pricey process. Here’s the deal: PangeAI’s geospatial AI platform lets Sky Blue dodge the usually...